BRIEF-Evelo Biosciences, Abdul Latif Jameel Health Announce Strategic Collaboration
BRIEF-Evelo Biosciences, Abdul Latif Jameel Health Announce Strategic Collaboration
* EVELO BIOSCIENCES & ABDUL LATIF JAMEEL HEALTH ANNOUNCE STRATEGIC COLLABORATION
* COLLABORATION TO DEVELOP AND COMMERCIALIZE EVELO’S LEAD INFLAMMATION PRODUCT CANDIDATE EDP1815 IN THE MIDDLE EAST, TURKEY, AND AFRICA
* THE COMPANY IS ALSO CONDUCTING A PHASE 2 CLINICAL TRIAL FOR EDP1815 IN PSORIASIS, AS WELL AS TWO TRIALS IN PATIENTS HOSPITALIZED WITH COVID-19
* TOGETHER, EVELO AND ABDUL LATIF JAMEEL HEALTH WILL WORK TO ADDRESS THE SIGNIFICANT DISPARITY IN ACCESS TO MEDICAL CARE IN THE FASTEST-GROWING POPULATIONS AND GROWTH ECONOMIES OF THE DEVELOPING WORLD
* UNDER THE TERMS OF THE AGREEMENT, EVELO RECEIVED AN UPFRONT PAYMENT AND EQUITY INVESTMENT
* EVELO WILL BE RESPONSIBLE FOR THE DEVELOPMENT AND MANUFACTURING OF EDP1815, WHILST ABDUL LATIF JAMEEL HEALTH WILL BE RESPONSIBLE FOR REGULATORY SUBMISSIONS AND COMMERCIALIZATION ACTIVITIES IN THE AGREED-UPON REGIONS
* EVELO AND ABDUL LATIF JAMEEL HEALTH WILL PARTICIPATE IN A 50:50
Further company coverage:
((Reuters.Briefs@thomsonreuters.com;)
March 23 (Reuters) - EVELO BIOSCIENCES INC :
* EVELO BIOSCIENCES & ABDUL LATIF JAMEEL HEALTH ANNOUNCE STRATEGIC COLLABORATION
* COLLABORATION TO DEVELOP AND COMMERCIALIZE EVELO’S LEAD INFLAMMATION PRODUCT CANDIDATE EDP1815 IN THE MIDDLE EAST, TURKEY, AND AFRICA
* THE COMPANY IS ALSO CONDUCTING A PHASE 2 CLINICAL TRIAL FOR EDP1815 IN PSORIASIS, AS WELL AS TWO TRIALS IN PATIENTS HOSPITALIZED WITH COVID-19
* TOGETHER, EVELO AND ABDUL LATIF JAMEEL HEALTH WILL WORK TO ADDRESS THE SIGNIFICANT DISPARITY IN ACCESS TO MEDICAL CARE IN THE FASTEST-GROWING POPULATIONS AND GROWTH ECONOMIES OF THE DEVELOPING WORLD
* UNDER THE TERMS OF THE AGREEMENT, EVELO RECEIVED AN UPFRONT PAYMENT AND EQUITY INVESTMENT
* EVELO WILL BE RESPONSIBLE FOR THE DEVELOPMENT AND MANUFACTURING OF EDP1815, WHILST ABDUL LATIF JAMEEL HEALTH WILL BE RESPONSIBLE FOR REGULATORY SUBMISSIONS AND COMMERCIALIZATION ACTIVITIES IN THE AGREED-UPON REGIONS
* EVELO AND ABDUL LATIF JAMEEL HEALTH WILL PARTICIPATE IN A 50:50
Further company coverage:
((Reuters.Briefs@thomsonreuters.com;)
路透3月23日电-EVELO Biosciences Inc:*EVELO Biosciences和Abdul Latif Jameel Health宣布战略合作*合作在中东、土耳其和非洲开发EVELO的主要候选炎症产品EDP1815并将其商业化*该公司还在进行EDP1815治疗牛皮癣的第二阶段临床试验,以及两项针对新冠肺炎住院患者的试验*EVELO和Abdul Latif Jameel Health将共同努力解决发展中世界增长最快的人口和增长的经济体在获得医疗保健方面的严重差距*根据协议条款,EVELO收到预付款和股权投资*EVELO将负责EDP1815的开发和制造,而Abdul Latif Jameel Health将负责商定地区的监管提交和商业化活动*EVELO和Abdul Latif Jameel Health将参加A 50:50进一步的公司报道:(Reurs.Briefs@thomsonreurs.com;)
译文内容由第三方软件翻译。
风险及免责提示
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧